Document is current
Any future updates will be listed below
-
Authors
Mehra, Tarun
Menges, Dominik
Gosztonyi, Benedict
Miglino, Nicola
Ring, Alexander
Boos, Laura
Sobottka, Bettina
,
Aebersold, Rudolf
Ak, Melike
Al-Quaddoomi, Faisal S.
Albert, Silvana I.
Albinus, Jonas
Alborelli, Ilaria
Andani, Sonali
Attinger, Per-Olof
Bacac, Marina
Baciu-Drăgan, Monica-Andreea
Baumhoer, Daniel
Beck-Schimmer, Beatrice
Beerenwinkel, Niko
Beisel, Christian
Bernasconi, Lara
Bertolini, Anne
Bodenmiller, Bernd
Bonilla, Ximena
Bosshard, Lars
Calgua, Byron
Casanova, Ruben
Chevrier, Stéphane
Chicherova, Natalia
Coelho, Ricardo
D’Costa, Maya
Danenberg, Esther
Davidson, Natalie R.
Dummer, Reinhard
Engler, Stefanie
Erkens, Martin
Eschbach, Katja
Esposito, Cinzia
Fedier, André
Ferreira, Pedro F.
Ficek-Pascual, Joanna
Frei, Anja L.
Frey, Bruno
Goetze, Sandra
Grob, Linda
Gut, Gabriele
Günther, Detlef
Haeuptle, Pirmin
Heinzelmann-Schwarz, Viola
Herter, Sylvia
Holtackers, Rene
Huesser, Tamara
Immer, Alexander
Irmisch, Anja
Jacob, Francis
Jacobs, Andrea
Jaeger, Tim M.
James, Alva R.
Jermann, Philip M.
Kahles, André
Kahraman, Abdullah
Koelzer, Viktor H.
Kuebler, Werner
Kuipers, Jack
Kunze, Christian P.
Kurzeder, Christian
Lehmann, Kjong-Van
Levesque, Mitchell
Lischetti, Ulrike
Lombardo, Flavio C.
Lugert, Sebastian
Maass, Gerd
Manz, Markus G.
Markolin, Philipp
Mehnert, Martin
Mena, Julien
Metzler, Julian M.
Miglino, Nicola
Milani, Emanuela S.
Moch, Holger
Muenst, Simone
Murri, Riccardo
Ng, Charlotte KY
Nicolet, Stefan
Nowak, Marta
Lopéz, Monica Nunez
Pedrioli, Patrick GA
Pelkmans, Lucas
Piscuoglio, Salvatore
Prummer, Michael
Prélot, Laurie
Rimmer, Natalie
Ritter, Mathilde
Rommel, Christian
Rosano-González, María L.
Rätsch, Gunnar
Santacroce, Natascha
del Castillo, Jacobo Sarabia
Schlenker, Ramona
Schwalie, Petra C.
Schwan, Severin
Schär, Tobias
Senti, Gabriela
Shao, Wenguang
Singer, Franziska
Sivapatham, Sujana
Snijder, Berend
Sobottka, Bettina
Sreedharan, Vipin T.
Stark, Stefan
Stekhoven, Daniel J.
Tanna, Tanmay
Theocharides, Alexandre PA
Thomas, Tinu M.
Tolnay, Markus
Tosevski, Vinko
Tuncel, Mustafa A.
Tusup, Marina
Drogen, Audrey Van
Vetter, Marcus
Vlajnic, Tatjana
Weber, Sandra
Weber, Walter P.
Wegmann, Rebekka
Weller, Michael
Wendt, Fabian
Wey, Norbert
Wicki, Andreas
Wildschut, Mattheus HE
Wollscheid, Bernd
Yu, Shuqing
Ziegler, Johanna
Zimmermann, Marc
Zoche, Martin
Zuend, Gregor
Koelzer, Viktor Hendrik
Moch, Holger
Toussaint, Nora C.
Levesque, Mitchell
Ramelyte, Egle
Mangana, Johanna
Dummer, Reinhard
Wicki, Andreas
-
Funding
Funding for this research was provided by:
Swiss Cancer Foundation
Dr. Arnold U. und Susanne Huggenberger-Bischoff Stiftung zur Krebsforschung
F. Hoffmann-La Roche, Switzerland
University Hospital of Zurich
Universität Zürich
Universitätsspital Basel
Promedica Stiftung
- License Information
-
More Information
Article History
Received: 21 July 2025
Accepted: 27 November 2025
First Online: 17 December 2025
Competing interests
: T.M., A.R., D.M., N.C.T., N.M., L.B., B.S., B.G., and A.W. declare no competing interests. V.H.K. reports being an invited speaker for Sharing Progress in Cancer Care (SPCC) and Indica Labs; advisory board of Takeda; and sponsored research agreements with Roche and IAG, all unrelated to the current study. V.H.K. is a participant in a patent application on the assessment of cancer immunotherapy biomarkers by digital pathology; a patent application on multimodal deep learning for the prediction of recurrence risk in cancer patients, and a patent application on predicting the efficacy of cancer treatment using deep learning. E.R. has intermittent project focused consultant/advisory relationships or has received speaker fees and/or travel support from Pierre Fabre, Regeneron, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Kyowa Kirin, and Eli-Lilly, outside of the submitted work. J.M. has intermittent project focused consultant/advisory relationships or has received speaker fees from Merck Sharp & Dohme, Novartis, Janssen, Bristol Myers Squibb and Pierre Fabre and has received travel support from Sunpharma, L’ Oreal, Merck Sharp & Dohme, Bristol Myers and Squibb und Pierre Fabre outside of the submitted work. M.L. is a co-founder and board member of Oncobit and has received unrelated research funding from Roche, Novartis, Bacoba, Oncobit, Scailyte, Molecular Partners, and Leica. R.D. has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, T3 Pharma, MaxiVAX SA, Pfizer and Simcere outside the submitted work. R.D. is a Senior medical advisor of the company Oncobit. H.M. declares obtaining research funding for his institution by Roche AG.
